The three mammalian Raf serine/threonine protein kinases mediate the transduction of proliferative and differentiative signals from cell surface receptors to the nucleus. In vertebrates, Raf signaling has been implicated in the progression of mouse embryos through the two-cell stage and in the induction of posterior mesoderm. However, mouse embryos mutant for each of the Raf genes exhibit no developmental defects before mid-gestation. Here we describe the phenotype of mouse mutants with different combinations of mutant Craf-1 and Braf alleles. Our results show that Raf signaling is indeed indispensable for normal development beyond the blastocyst stage. However, due to a signi®cant redundancy between Craf-1 and Braf, either gene is suf®cient for normal development until mid-gestation. The molecular and developmental mechanisms for this redundancy were investigated by monitoring the expression of Raf genes throughout embryogenesis and by biochemical studies in mutant cell lines. q
Introduction
The Ras/Raf/MEK/MAP kinase cascade is an essential component of intracellular signaling pathways from activated cell-surface receptors to transcription factors in the nucleus in all metazoan organisms. Raf serine/threonine protein kinases are key components of these pathways and their role in a variety of developmental processes in invertebrate model organisms is well established. Mutations of the single Drosophila Raf gene, Draf, perturb the determination of the dorsoventral polarity of the egg (Brand and Perrimon, 1994) , the formation of the terminal structures of the larva (Ambrosio et al., 1989) , and the speci®cation of the R7 photoreceptor (Dickson et al., 1992) . In C. elegans, CeRaf is required for vulval differentiation (Han et al., 1993) .
In mammals there are three highly conserved Raf genes (Araf, Braf, and Craf-1) that are the result of duplications of the entire genome and its segments during vertebrate evolution followed by functional adaptation of new Raf paralogs (Holland et al., 1994) . Biochemical studies suggest differential utilization of Raf isozymes (Erhardt et al., 1995; Pritchard et al., 1995; Jaiswal et al., 1996; Marais et al., 1997) . However, the frequent co-expression of Raf isozymes and their multiple activators and effectors in one cell lineage impedes the full understanding of their speci®c roles. The elucidation of these roles is important due to the involvement of the Ras/Raf/MEK/MAP kinase cascade in human disorders. Mutations of the Raf activator Ras are present in 30% of human cancers (Khosravi-Far and Der, 1994; Abrams et al., 1996) and their transforming potential is dependent on Raf (Kolch et al., 1991) . Consequently, Raf isozymes are considered attractive targets for tumor therapies. Recently it was shown that antisense Craf-1 oligonucleotides display potent activity against a broad spectrum of tumor types in mouse models. These oligonucleotides are currently being tested in Phase I clinical trails (Monia, 1997) .
To elucidate the speci®c roles of mammalian Raf isozymes we and others have generated mouse strains with disrupted Raf genes. Two out of three Raf genes (Braf and Craf-1) are indispensable for life since disruption of either of them invariably results in embryonic or perinatal lethality. Mice de®cient in Braf die between E10.5 and E12.5 of vascular defects caused by excessive death of endothelial cells (Wojnowski et al., 1997) . Craf-1 de®-ciency results in defects of the placenta, lungs and skin of homozygous mutants. Craf-1 homozygous mutants die between E10.5 and P0, depending on the genetic background of the embryos (Wojnowski et al., 1998) . Additionally, the phenotype of Araf mutants depends on genetic background-speci®c modi®ers. Thus, on a C57Bl/6 genetic background Araf-de®cient mice die between 7 and 21 days post-partum displaying gastro-intestinal and neurological defects including megacolon, abnormal movements, abnormal proprioception and excessive agitation. In contrast, on a 129/OLA background Araf mutants survive to adulthood, and only develop a subset of the neurological defects (Pritchard et al., 1996) . The phenotypical differences among the Raf-de®cient mutants suggested the existence of exclusive roles for the individual Raf isozymes in mammalian development.
Craf-1 has been reported to be indispensable for the progression of mouse embryos through the two-cell stage, albeit not for subsequent development to morulae and blastocysts (Yamauchi et al., 1994) . In Xenopus, injections of animal cap explants with a dominant-negative Craf-1 mutant resulted in a severe posterior truncation of the tadpoles. These observations indicated that in Xenopus Raf activity is required for the FGF-dependent induction of posterior mesoderm (MacNicol et al., 1993) . Thus, we were somewhat surprised by the lack of any major defects in all murine Raf mutants before mid-gestation. Here we describe the phenotype of mutants with different combinations of mutant Craf-1 and Braf alleles. Our results show that Raf signaling is indeed indispensable for normal development beyond the blastocyst stage. However, Craf-1 and Braf exhibit a signi®cant redundancy during the ®rst half of gestation so that normal development can be accomplished by either of these two genes. The molecular mechanism for this redundancy was investigated by monitoring the expression of Raf genes throughout embryogenesis and by biochemical studies in primary cell lines.
Results

Phenotypic characterization of Craf-1/Braf double mutants
To test the hypothesis whether the phenotype of Craf-1 or Braf mutants is exacerbated in the absence of functional allele(s) of the other gene, we crossed the Craf-1 mutation into a Braf mutant background. Mating Craf-1 1/2 and Braf 1/2 heterozygous mice generated double heterozygous Craf-1 1/2
/Braf
1/2 mice on a mixed 129/CD1 genetic background. The double-heterozygous mice were then intercrossed and embryos isolated at E10.5 or E8.5 and scored for abnormalities. Matings between Craf-1 1/2 /Braf 1/2 mice produced nine different combinations of wild-type and mutant alleles of Craf-1 and Braf (Fig. 1) 
1/1 mutants were smaller than wild-type littermates, their posterior region appeared underdeveloped and some of them failed to complete axial rotation ( Fig. 2A) . The death of Craf-1 1/1 / Braf 2/2 mutants resulted from vascular defects that become manifest at this stage of development (Wojnowski et al., 1997) . All these observations were in agreement with our recent analysis of single homozygous Craf-1 (Wojnowski et al., 1998) and Braf (Wojnowski et al., 1997) mutants.
Further loss of Raf alleles increased dramatically the extent of abnormalities (Figs. 1 and 2B±D). Loss of three out of four copies of Braf and Craf-1 (Craf-1
2/2 genotypes) resulted in either a developmental delay or arrest, and ultimately in the death of 90% of the embryos before E10.5. In addition to growth retardation and failure of axial rotation, the phenotypical abnormalities in these embryos included various degrees of underdevelopment of the brain and head structures, heart and limbs as well as an abortive somite formation and a failure of the chorioallantoic fusion. Most severely affected embryos were arrested at the early stages of gastrulation.
Disruption of all four copies of Braf and Craf-1 further exacerbated the developmental delay of the embryos. Double Craf-1 2/2 /Braf 2/2 mutants were present in maternal deciduas as small clumps of cells of approximately 0.5 mm 
1/2 double heterozygous mice. The developmental stage of seven embryonal structures (axis, limbs, spinal cord, brain, cranio-facial structures, heart and vessels) was assessed and abnormalities were assigned numeric values of 0.5 points for`mild', and of 1 point for`severe' defects (see Section 4). Note that developmental abnormalities increase with the progressive loss of Braf and Craf-1 alleles.
in diameter and they were encountered at the expected Mendelian frequency until E8.5. Serial sectioning revealed the presence of several hundred cells divided into two distinct lineages, closely resembling the inner cell mass and the trophoblast cells of the mouse blastocyst (Fig. 3) . Interestingly, despite the developmental arrest, the embryos continued to grow until around E8.5 as evident by the presence of mitotic ®gures at this time-point (inset of Fig.  3 ). The duration of the cell cycle was estimated as 16±20 h from the number of mitotic ®gures (2%), and was signi®-cantly longer than that of early wild-type embryos (Hogan et al., 1986) . Thus, disruption of both Craf-1 and Braf abrogates the differentiation of all embryonic lineages, but it has no arresting effect on the cell proliferation and implantation of the embryo. Collectively, these results revealed dosagedependent interactions between these two genes during the ®rst half of gestation.
Expression of Raf isozymes during embryogenesis and post-natally
We investigated the expression of all three murine Raf genes at selected developmental stages by means of RNA and protein analysis. The experiments were performed on whole-cell lysates of embryonic stem (ES) cells and on RNA samples from E7.5±E17.5 mouse embryos and selected adult tissues. Western blotting of extracts of ES cells using antibodies speci®c for the individual Raf isozymes demonstrated that all three Raf genes are expressed in ES cells established from the inner cell mass of E3.5 mouse blastocysts (Fig. 4A) . The Raf proteins expressed in the ES cells are of the same apparent size as the major isoforms expressed in adult tissues, i.e. 68 kDa for Araf, 97 and 94 kDa for Braf, and 74 kDa for Craf-1. The expression of all Raf genes is maintained throughout embry- ogenesis as indicated by Northern blotting and RT-PCR using isozyme-speci®c cDNA probes and primer pairs, respectively (Fig. 4B,C) . Northern blots of polyA 1 RNA samples from E7.5±E17.5 mouse embryos with isozymespeci®c probes yield estimates of the expression levels of Raf genes throughout embryogenesis. As shown in Fig. 4C , transcripts encoding the individual isozymes are expressed at similar levels between E7.5 and E17.5, except for Araf which undergoes strong upregulation at E17.5.
Craf-1 was initially reported to be the only Raf gene with a ubiquitous expression post-natal expression pattern (Storm et al., 1990) . However, the phenotype of Araf mouse mutants (Pritchard et al., 1996) and a detailed analysis of Braf splice variants (Barnier et al., 1995) suggested a broader spectrum of target tissues for these genes than assumed initially. As shown in Fig. 4D , Craf-1 was expressed at similar levels in all seven adult tissues examined. Consistent with a recent study of Braf protein expression (Barnier et al., 1995) , Braf transcripts were detected in all tissues examined except skeletal muscle. The highest expression levels of Braf were observed in the brain and testis. Similarly, Araf transcripts were detected in all tissues examined. The detection of several different transcripts of Braf is consistent with the existence of different Braf protein splice variants (Barnier et al., 1995 #759) , whereas the signi®cance of the two different Araf transcripts (2.0 and 2.9 kbp) remains to be elucidated. The transcripts encoding the individual Raf isozymes in adult tissues were of the same size as during embryogenesis with the exception of a 2.6 kb Braf transcript detected in testis. This 2.6 kb transcript is expressed exclusively in post-meiotic spermatids (Wadewitz et al., 1993) .
In situ hybridization experiments were performed to determine the tissue distribution of Raf transcripts. Saggital sections from E15.5 mouse embryos were hybridized with isozyme-speci®c Raf cDNA probes that recognize exclusively the isozyme-speci®c transcripts in Northern blots. As shown in Fig. 5 , all Raf genes are ubiquitously expressed in murine organs resulting in very similar expression patterns for these genes at this stage. Taken together, these results show that all Raf genes are transcribed throughout embryogenesis and may be co-expressed in multiple tissues. The broad expression of Raf transcripts continues post-natally.
Biochemical characterization of Raf mutants
We investigated the relationship between Braf and Craf-1 by biochemical methods in primary ®broblast cell lines derived from wild-type and Braf or Craf-1 homozygous mutant embryos. The activity of Braf protein kinase was investigated in serum-starved wild-type and Craf-1 2/2 mutant homozygous ®broblasts stimulated with epidermal growth factor (EGF), a known activator of Craf-1 kinase (Boonstra et al., 1995; Wixler et al., 1996) . Following stimulation and cell lysis, Braf was immuno-precipitated and its activity tested in a coupled kinase assay with recombinant MEK1, MAP kinase, and [ (Fig. 6B) . EGF treatment increased the activity of Craf-1 kinase in wild-type, but not homozygous mutant cells. These results suggest that Craf-1 and Braf may cooperate in the activation of MAP kinase.
We have previously shown that disruption of Craf-1 had no dominant-negative effect on the activation of MAP kinase mediated by other pathways (Wojnowski et al., 1998) . Fig. 6C shows the activity of MAP kinase in lysates of wild-type and Braf homozygous mutant ®broblasts stimulated with EGF. Unlike in Craf-1-de®cient cells (Wojnowski et al., 1998) , there is no activation of MAP kinase by EGF in Braf-de®cient cells.
Discussion
We have previously shown that both Braf and Craf-1 are essential for embryonic development as indicated by the embryonic or perinatal lethality of the respective homozygous mutant embryos or pups (Wojnowski et al., 1997 (Wojnowski et al., , 1998 . Here we present an analysis of embryos mutant for both genes. Our results suggest that in addition to their unique functions, Braf and Craf-1 cooperate in the transduction of many proliferative and differentiative signals. Indeed, introduction of Braf mutant alleles onto Craf-1-de®-cient background exacerbates the extent of the developmental delay. Most embryos de®cient in either Craf-1 or Braf on a mixed 129/CD1 genetic background survive until E10.5 and many display no visible abnormalities. On the other Fig. 5 . Bright-®eld (left panel) and dark-®eld (right panel) images of E15.5 saggital mouse embryo sections hybridized to Araf-, Braf-, and Craf-1-speci®c probes. F, forebrain; H, heart; K, kidney; Li, liver; Lu, lung; M, midbrain; SM, skeletal muscle; SC, spinal cord; SG, submandibular gland; T, thymus; W, whiskers. hand, double homozygous mutants appear as if the two cell types normally found in early blastocysts, trophoectoderm and inner mass cells, continued to proliferate without any further differentiation. Such a developmental block could be explained by the indispensability of Craf-1 and Braf in the speci®cation of only one early critical cell lineage such as the endoderm. However, defects observed in embryos with mutations in three out of four Craf-1 and Braf alleles point to a role for Raf signaling in all major developmental processes before mid-gestation (gastrulation, neurulation, turning, early organogenesis). A comparison of the respective single-gene mutant phenotypes with that of double mutants indicates that normal development during the ®rst half of gestation can be accomplished by either Craf-1 or Braf. This suggests a signi®cant redundancy between these genes, consistent with the high homology between Craf-1 and Braf proteins. Previously, similar functional redundancies have been demonstrated for the families of Raf regulators, Ras (Johnson et al., 1997) , and GAP (Henkemeyer et al., 1995) .
Functional redundancy between Braf and Craf-1 would require these proteins to be co-expressed. Expression of Craf-1 has been documented for mouse eggs and preimplantation embryos (Pal et al., 1993) , whereas all murine Raf transcripts have been found in several selected tissues at E16 (Storm et al., 1990) . We found all murine Raf isozymes expressed throughout embryogenesis and in a majority of the tissues selected also post-natally. Beginning at midgestation, Craf-1 and Braf acquire essential, non-redundant functions (Fig. 7) . The resulting embryonic lethality precludes at present the elucidation of functional redundancy between these genes in the second half of gestation but should be possible in the future, perhaps by means of rescue of the vascular defect in Braf-de®cient mice. However, the broad, apparently ubiquitous expression of all murine genes observed at E15.5 and the phenotypical similarities such as growth retardation among Raf mutants suggest that an overlap in Raf function may occur later in embryogenesis.
Craf-1 has been implicated in the progression of mouse embryos through the two-cell stage (Yamauchi et al., 1994) . In Xenopus, injections of animal cap explants with a dominant-negative Craf-1 mutant suggested an essential role for Craf-1 in the induction of the mesoderm (MacNicol et al., 1993) . One possible explanation for the differences between these studies and the much milder phenotype of Craf-1 homozygous knockouts (Wojnowski et al., 1998) are the techniques used to perturb Raf gene function. Due to the high homology among Raf proteins, the overexpression of Craf-1 mutants could have interfered with the function of multiple Raf isoforms. This possibility is supported by the observation that the Craf-1 homozygous phenotype is dramatically exacerbated in the absence of functional Braf alleles.
Increasing the number of mutant Braf and Craf-1 alleles exacerbates the extend of developmental abnormalities suggesting that Raf-dependent signaling is transmitted by both gene products. However, embryos lacking two identical alleles of either Braf or Craf-1 invariably die, whereas most embryos lacking two different alleles (i.e. double heterozygous Craf-1 1/2 /Braf 1/2 mutants) are born and display no visible abnormalities. Thus, a simple genedosage effect of mutant Braf and Craf-1 alleles is unlikely the only cause for the progressively severe phenotype in embryos mutant for alleles of both genes. This assumption is supported by the observation that both isozymes are required for the activation of the MAP kinase (Fig. 6A,B) . The molecular basis of this interaction between Craf-1 and Braf is unknown. However, it has recently been shown that Craf-1 is activated upon homodimerization (Farrar et al., 1996; Luo et al., 1996) . Craf-1/Braf heterodimers would provide a molecular basis for the synergistic interactions reported here, and preliminary evidence indicates that such heterodimers can be detected in these MEFs (data not shown).
The biochemical data that EGF failed to stimulate either Braf in Craf-1-de®cient ®broblasts and/or Craf-1 in Brafde®cient ®broblasts might appear to contradict the results of the phenotypical analysis of mutants de®cient in either single gene. Indeed, disruption of either single gene has no major consequences on the embryonic development during the ®rst half of gestation. Among possible explanations it is conceivable that, unlike EGF, other growth factors which control development can activate either Craf-1 or Braf when the other isoform is not expressed. It is also conceivable that one of the other upstream activators of MAP kinases such as Mos, Tpl2, MEKK, MEKK2 and MEKK3 (Widmann et al., 1999) may partially substitute for the actions of one or both isoforms of Raf. In a previous study we have demonstrated that Raf-independent activators are likely to be utilized since disruption of Craf-1 had no dominant-negative effect on the activation of MAP kinase (Wojnowski et al., 1998) . The results presented here suggest Fig. 7 . Model of interaction between Raf genes during mammalian development, based on references (Pritchard et al., 1996; Wojnowski et al., 1997 Wojnowski et al., , 1998 and this paper. Braf and Craf-1 have redundant functions; beginning at mid-gestation each gene acquires non-redundant, essential functions. A possible redundancy with Araf remains to be established.
that MAP kinase activation in the absence of Craf-1 is not mediated by Braf, since Braf does not phosphorylate MAP kinase in the absence of a functional Craf-1 protein.
Methods
Embryo analysis
Midday of the vaginal plug was taken as day 0.5 postcoitum (E0.5) in the staging of embryos. For general histology, dissected embryos were ®xed in 4% paraformaldehyde/ 1£ PBS, embedded in wax, sectioned, and counterstained with hematoxylin/eosin. Embryos from intercrosses between double-heterozygous Craf-1 1/2 /Braf 1/2 mice were dissected at E10.5 and scored for defects in seven embryonic structures: axis, limbs, spinal cord, brain, cranio-facial structures, heart, and vessels. Defects were classi®ed on a subjective scale as`mild' with a score of 0.5 or`severe' with a score of 1. For example, a developmental delay in limb development of 12 h was considered mild' while a delay of more than 24 h, or the complete absence of limb development was considered`severe'. Consequently, an embryo with a score of 0 was normally developed, while an embryo with a score of 7 had severe abnormalities in all structures that were assessed.
Gene expression studies
The membrane was then probed with an HRP-conjugated goat anti-rabbit secondary antibody followed by visualization by chemiluminescence.
